Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jul 7, 2017
Company News

Acer finds public path via Opexa merger

BioCentury | Jul 3, 2017
Company News

Acer finds public path via Opexa merger

BioCentury | Feb 1, 2017
Clinical News

Tcelna: Ph IIb Abili-T data

BioCentury | Nov 4, 2016
Company News

Opexa restructuring

BioCentury | Apr 4, 2016
Finance

Restructuring watch

BioCentury | Mar 21, 2016
Company News

Opexa autoimmune news

BioCentury | May 18, 2015
Company News

Opexa, Merck KGaA deal

BioCentury | Mar 9, 2015
Clinical News

Imilecleucel-T: Completed Phase IIb enrollment

BioCentury | Nov 24, 2014
Emerging Company Profile

Progressive play

Medday's MD 1003 could reverse disease progression in advanced MS
BioCentury | Oct 16, 2014
Translation in Brief

Translational tidbits

Items per page:
1 - 10 of 17